Today we announced operating and financial results for Q2 2023, with net sales up more than 20% year-over-year in consecutive quarters! Read more in the release and join our webcast today at 5:00 p.m. ET for all the latest updates: https://t.co/KE8R1578Vh
Join the MIMEDX leadership team for our second quarter 2023 operating and financial results conference call on August 1. All the details + webcast information available here: https://t.co/naTXs4Jp8o
Today at 5:00 p.m. ET, our leadership team will cover operating and financial results for Q1 2023—our strongest start in several years, highlighted by nearly 22% growth in net sales year-over-year. Read more and stream the webcast here: https://t.co/YIaD4mFzRa
If you're attending the @MohsCollege annual meeting this year, be sure to stop by booth #100 to learn about placental-based allografts and their use in Mohs surgery. See you next week! #ACMS2023#Mohssurgery
Join the MIMEDX leadership team for our first quarter 2023 operating and financial results conference call on May 2. All the details + webcast information available here: https://t.co/AujOdT9eBx
The Office of Inspector General has recently published a report detailing the need for pricing transparency in Medicare’s reimbursement of skin substitutes in the private physician office setting. Read more about our support for these findings: https://t.co/DCIiAUcIcZ
Today, we announced our operating and financial results for Q4 & FY 2022, which included the Company’s highest quarterly net sales since Q4 2019. Read more and join our webcast for all the latest updates: https://t.co/4qcCu7Prsk
Join the MIMEDX leadership team for our Q4 & FY 2022 operating and financial results conference call on February 28. All the details + webcast information available here: https://t.co/ILmGhoeCtx
Please join us in welcoming Joe Capper as CEO at MIMEDX! An accomplished MedTech and Life Sciences executive, Joe joins with nearly 30 years of experience to lead our efforts to advance the science and innovate the field of placental biologics. Read more: https://t.co/DS10DIwPvJ
Today, MIMEDX reaffirmed fourth quarter and full year 2022 net sales expectations and provided corporate updates, including commentary on the evolving Medicare reimbursement landscape. View the press release for the latest details: https://t.co/vGq1mXEHcZ
Today, we announced significant progress in our international market expansion with the commercial launch of EPIFIX® in Japan and an exclusive distribution agreement with GUNZE Medical. Read more: https://t.co/uwBpS74yM8
We are pleased to announce an agreement with Turn Therapeutics to accelerate our product development pipeline with a proprietary antimicrobial technology platform. Learn more: https://t.co/C89gI74y0C
We’re back in NYC for the @Piper_Sandler 34th Annual Healthcare Conference! Live stream the event to see MIMEDX senior management present recent highlights: https://t.co/HeMXY4hLhD
Today, we’re presenting at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in NYC. Tune in to the webcast at 9:30 a.m. ET: https://t.co/5JXUAiEBqa
Join us in-person or stream online as our leadership team participates in two investor conferences this month. For all the details visit: https://t.co/vMxheWC2G7
Reminder: Today at 5:00 p.m. ET, the MIMEDX senior management team will discuss Q3 2022 operating and financial results. Join us for a live webcast here: https://t.co/2sRKHkIwoc $MDXG
The MIMEDX senior management team will present Q3 2022 operating and financial results on Wednesday, November 2 at 5:00 p.m. ET. Full details: https://t.co/Us734geEZW $MDXG